Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Income from Continuing Operations (2020 - 2025)

Journey Medical (DERM) has disclosed Income from Continuing Operations for 6 consecutive years, with 2315000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 3.14% year-over-year to 2315000.0, compared with a TTM value of 8542000.0 through Sep 2025, up 53.41%, and an annual FY2024 reading of 14671000.0, down 280.77% over the prior year.
  • Income from Continuing Operations was 2315000.0 for Q3 2025 at Journey Medical, up from 3736000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 16789000.0 in Q3 2023 and bottomed at 21751000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 5379473.68, with a median of 4073000.0 recorded in 2025.
  • The sharpest move saw Income from Continuing Operations crashed 36810.34% in 2021, then soared 266.56% in 2023.
  • Year by year, Income from Continuing Operations stood at 21751000.0 in 2021, then skyrocketed by 51.07% to 10642000.0 in 2022, then soared by 79.86% to 2143000.0 in 2023, then soared by 173.82% to 1582000.0 in 2024, then plummeted by 246.33% to 2315000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for DERM at 2315000.0 in Q3 2025, 3736000.0 in Q2 2025, and 4073000.0 in Q1 2025.